<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FOSAMPRENAVIR CALCIUM</span><br/>(fos-am-pre'na-vir)<br/><span class="topboxtradename">Lexiva<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiretroviral agent</span>; <span class="classification">protease inhibitor</span><br/><b>Prototype: </b>Saquinavir<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>700 mg tablet</p>
<h1><a name="action">Actions</a></h1>
<p>Fosamprenavir is a prodrug rapidly converted to amprenavir. Amprenavir is an HIV-1 protease inhibitor that binds to the active
         site of HIV-1 protease. Binding prevents processing of viral Gag and Gag-Pol polyprotein precursors, resulting in formation
         of immature noninfectious viral particles.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits normal replication of the HIV virus rending the virus noninfectious.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of HIV infection in combination with other antiretroviral agents.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to any of the components of this product or to amprenavir; ergot derivatives, pimozide, midazolam, triazolam;
         coadministration of ritonavir, flecainide, and propafenone; severe hepatic impairment; pregnancy (category C), lactation.
         Safety and efficacy in pediatrics and patients &gt;65 y have not been established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Sulfa allergy; mild to moderate hepatic impairment; concurrent administration of amiodarone, bepridil, dihydroergotamine,
         ergotamine, flecainide, itraconazole, ketoconazole, lidocaine (systemic), midazolam, pimozide, propafenone, quinidine, triazolam,
         and tricyclic antidepressants; hepatic impairment; hemophilia.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 700 mg b.i.d. in combination with 100 mg ritonavir b.i.d. (preferred if previously on a protease inhibitor); or 1400 mg b.i.d.;
               or 1400 mg q.d. in combination with 200 mg ritonavir q.d.<br/><br/><span class="impairmenttitle">Hepatic Impairment</span><br/>
<b>Mild to Moderate Impairment</b> Reduce dose to 700 mg b.i.d. without ritonavir; not recommended in severe hepatic impairment<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Ensure that patient is not receiving drugs contraindicated with fosamprenavir.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fatigue. <span class="typehead">CNS:</span>
<span class="speceff-common">Oral/perioral paresthesia,</span> peripheral paresthesia, depression, mood disorders. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, diarrhea,</span> abdominal pain, taste disorders, increased triglycerides, and hyperglycemia.  <span class="typehead">Skin:</span>
<i>Rash, </i>pruritus, <span class="speceff-life">Stevens-Johnson syndrome</span>. 
      <h1><a name="interactions">Interactions</a></h1>
      				Note: Interaction profile can be significantly affected by coadministration with <b>ritonavir.</b>
<span class="typehead">Drug:</span> Administration with <b>amiodarone,</b>
<b>bepridil,</b>
<b>dihydroergotamine,</b>
<b>ergotamine,</b>
<b>flecainide,</b>
<b>itraconazole,</b>
<b>ketoconazole,</b>
<b>lidocaine,</b>
<b>midazolam,</b>
<b>pimozide,</b>
<b>propafenone,</b>
<b>quinidine,</b>
<b>triazolam,</b> and <span class="classification">tricyclic antidepressants</span> may cause life-threatening reactions; <b>rifampin,</b>
<b>rifabutin,</b>
<span class="classification">oral contraceptives</span>, <b>phenobarbital,</b>
<b>phenytoin,</b>
<b>carbamazepine</b> decrease <b>amprenavir</b> concentrations; <b>amprenavir</b> may increase <b>dihydroergotamine,</b>
<b>ergotamine,</b>
<b>sildenafil</b> concentrations and toxicity; <b>amprenavir</b> may decrease <b>methadone</b> levels; monitor INR with <b>warfarin;</b> increased risk of myopathy and rhabdomyolysis with <b>lovastatin,</b>
<b>simvastatin;</b> may decrease antiviral effectiveness of <b>delavirdine or lopinavir/ritonavir.</b>
<span class="typehead">Herbal:</span>
<b>St. John's wort</b> may decrease antiretroviral activity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Prodrug is rapidly hydrolyzed to amprenavir (active component) by gut enzymes during absorption. <span class="typehead">Peak:</span> 2.5 h. <span class="typehead">Metabolism:</span> Metabolized in liver by CYP3A4. <span class="typehead">Elimination:</span> 14% excreted in urine, 75% excreted in feces. <span class="typehead">Half-Life:</span> 7.7 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Ensure that patient has provided a complete list of all prescription, nonprescription, or herbal drugs being used.</li>
<li>Monitor closely diabetics for loss of glycemic control.</li>
<li>Monitor males taking PDE5 inhibitors for erectile dysfunction for adverse events including hypotension, visual changes, and
            priapism. Report promptly.
         </li>
<li>Lab test: Baseline and periodic LFTs; periodic lipid profile; periodic blood glucose.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>If you miss a dose by &gt;4 h, wait and take the next dose at the regular time.</li>
<li>Do not take other prescription, nonprescription, or herbal drugs without consulting physician.</li>
<li>Monitor blood glucose more often than usual if diabetic.</li>
<li>To prevent pregnancy, use a barrier contraceptive in addition to hormonal contraception.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>